This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Creutzig, U. Articles by Lehrnbecher, T. Search for Related Content PubMed PubMed Citation Articles by Creutzig, U. Articles by Lehrnbecher, T.

Early Deaths and Treatment-Related Mortality in Children Undergoing Therapy for Acute Myeloid Leukemia: Analysis of the Multicenter Clinical Trials AML-BFM 93 and AML-BFM 98

From the Department of Pediatric Hematology and Oncology, University Children's Hospital, Muenster; Department of Pediatric Hematology and Oncology, University Children's Hospital, Frankfurt; Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany; St Anna Kinderspital and Children's Cancer Research Institute, Vienna, Austria; 2nd Medical Faculty, Charles University, Prague, Czech Republic

Address reprint requests to Ursula Creutzig, MD, AML-BFM Trial Center, University Children's Hospital Muenster, Department of Pediatric Hematology and Oncology, Albert-Schweitzer-Str 33, D-48129 Muenster, Germany; e-mail: ursula{at}creutzig.de

PURPOSE: The rates of early death (ED) and treatment-related mortality (TRM) are unacceptably high in children undergoing intensive chemotherapy for acute myeloid leukemia (AML). Better strategies of supportive care might help to improve overall survival in these children.

PATIENTS AND METHODS: In a retrospective study, we analyzed incidence, clinical features, and risk factors for lethal complications of 901 children enrolled onto the multicenter trials Acute Myeloid Leukemia-Berlin-Frankfurt-Muenster (AML-BFM) 93 and AML-BFM 98.

RESULTS: One hundred four patients (11.5%) enrolled onto the clinical trials AML-BFM 93 and AML-BFM 98 died shortly after diagnosis or as a result of treatment-related complications. Thirty-two patients (3.5%) died before (six patients) or during (26 patients) the first 14 days of treatment, mainly as a result of bleeding or leukostasis. Low performance status, hyperleukocytosis, and French-American-British type M5 were the main risk factors for a lethal event before day 15. After day 15, the predominant causes of death were complications caused by infections, particularly bacterial and fungal infections. The incidence of lethal infections was highest during induction therapy and decreased thereafter. When comparing both clinical trials, significantly fewer patients died within the first 6 weeks in AML-BFM 98 than in AML-BFM 93 (14 [3.5%] of 430 patients v 35 [7.4%] of 471 patients; P = .01).

CONCLUSION: To reduce the high incidence of ED and TRM in children with AML, early diagnosis and adequate treatment of complications are needed. Children with AML should be treated in specialized pediatric cancer centers only. Prophylactic and therapeutic regimens for better treatment management of bleeding disorders and infectious complications have to be assessed in future trials to ultimately improve overall survival in children with AML.

Supported by the Deutsche Krebshilfe.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

This article has been cited by other articles:

				G. J.L. Kaspers and C. M. Zwaan Pediatric acute myeloid leukemia: towards high-quality cure of all patients Haematologica, November 1, 2007; 92(11): 1519 - 1532. [Abstract] [Full Text] [PDF]

				T. Lehrnbecher, M. Zimmermann, D. Reinhardt, M. Dworzak, J. Stary, and U. Creutzig Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia Blood, February 1, 2007; 109(3): 936 - 943. [Abstract] [Full Text] [PDF]

				U. Creutzig, M. Zimmermann, T. Lehrnbecher, N. Graf, J. Hermann, C. M. Niemeyer, A. Reiter, J. Ritter, M. Dworzak, J. Stary, et al. Less Toxicity by Optimizing Chemotherapy, but Not by Addition of Granulocyte Colony-Stimulating Factor in Children and Adolescents With Acute Myeloid Leukemia: Results of AML-BFM 98 J. Clin. Oncol., September 20, 2006; 24(27): 4499 - 4506. [Abstract] [Full Text] [PDF]

				C. Langebrake, U. Creutzig, M. Dworzak, O. Hrusak, E. Mejstrikova, F. Griesinger, M. Zimmermann, and D. Reinhardt Residual Disease Monitoring in Childhood Acute Myeloid Leukemia by Multiparameter Flow Cytometry: The MRD-AML-BFM Study Group J. Clin. Oncol., August 1, 2006; 24(22): 3686 - 3692. [Abstract] [Full Text] [PDF]

				D. Steinbach, A. Schramm, A. Eggert, M. Onda, K. Dawczynski, A. Rump, I. Pastan, S. Wittig, N. Pfaffendorf, A. Voigt, et al. Identification of a Set of Seven Genes for the Monitoring of Minimal Residual Disease in Pediatric Acute Myeloid Leukemia Clin. Cancer Res., April 15, 2006; 12(8): 2434 - 2441. [Abstract] [Full Text] [PDF]